KAYLA BONE: Open Payments
NPI 1336875830 · FREDERICKTOWN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$720 in 44 payments from 12 companies in 2025. Trend: 2023 $368 · 2024 $390 · 2025 $720
Food & beverage: $720
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $299 |
| Lundbeck LLC | 5 | $86 |
| GlaxoSmithKline, LLC. | 4 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Novo Nordisk Inc | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 3 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $17 |
Products named: VRAYLAR, REXULTI, TRELEGY ELLIPTA, UBRELVY, CAPLYTA, ZENPEP, BREZTRI, Rybelsus.
Industry payments across MO — which companies pay providers there.
